Evidence map›Paper›PMID 28817787›Full record

ArticleCanadian journal of microbiology2017

Evaluation of the electron transfer flavoprotein as an antibacterial target in Burkholderia cenocepacia.

Maria S Stietz, Christina Lopez, Osasumwen Osifo, Marcelo E Tolmasky, Silvia T Cardona

Open access · greenAbstract read
In one paragraph

Article in Canadian journal of microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. A Riboflavin Transporter in Bdellovibrio exovorous JSS.Journal of molecular microbiology and biotechnology · 2019
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Maria S Stietza Department of Microbiology, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.
Christina Lopezb Department of Biological Science, Center for Applied Biotechnology Studies, California State University Fullerton, Fullerton, CA 92831-3599, USA.
Osasumwen Osifoa Department of Microbiology, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.
Marcelo E Tolmaskyb Department of Biological Science, Center for Applied Biotechnology Studies, California State University Fullerton, Fullerton, CA 92831-3599, USA.
Silvia T Cardonaa Department of Microbiology, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.
University of Manitoba · CA

Funding

DEALING WITH ANTIBIOTIC RESISTANCE--ANTISENSE TECHNOLOGYR15AI047115 · NIAID · CALIFORNIA STATE UNIVERSITY FULLERTON · PI TOLMASKY, MARCELO E · 2000 to 2022
$1.8M
NIAID NIH HHS R15 AI047115
6 · The paper itself

Abstract

There are hundreds of essential genes in multidrug-resistant bacterial genomes, but only a few of their products are exploited as antibacterial targets. An example is the electron transfer flavoprotein (ETF), which is required for growth and viability in Burkholderia cenocepacia. Here, we evaluated ETF as an antibiotic target for Burkholderia cepacia complex (Bcc). Depletion of the bacterial ETF during infection of Caenorhabditis elegans significantly extended survival of the nematodes, proving that ETF is essential for survival of B. cenocepacia in this host model. In spite of the arrest in respiration in ETF mutants, the inhibition of etf expression did not increase the formation of persister cells, when treated with high doses of ciprofloxacin or meropenem. To test if etf translation could be inhibited by RNA interference, antisense oligonucleotides that target the etfBA operon were synthesized. One antisense oligonucleotide was effective in inhibiting etfB translation in vitro but not in vivo, highlighting the challenge of reduced membrane permeability for the design of drugs against B. cenocepacia. This work contributes to the validation of ETF of B. cenocepacia as a target for antibacterial therapy and demonstrates the utility of a C. elegans liquid killing assay to validate gene essentiality in an in vivo infection model.

Indexed as

AnimalsAnti-Bacterial AgentsBurkholderia cenocepaciaCaenorhabditis elegansCell Membrane PermeabilityCiprofloxacinElectron-Transferring FlavoproteinsMeropenemMutationOligonucleotides, AntisenseRNA InterferenceThienamycinsAnti-Bacterial AgentsCiprofloxacinElectron-Transferring FlavoproteinsMeropenemOligonucleotides, AntisenseThienamycinsantibacterial targetsantisense oligonucleotidesBurkholderia cenocepaciaCaenorhabditis eleganscellules persistantes dormantescibles antibactériennescystic fibrosiselectron transfer flavoprotein (ETF)essential genesfibrose kystiqueflavoprotéine de transfert d’électrons (ETF)gènes essentielsoligonucléotides antisenspersister cells

Identifiers

PMID28817787
PMCPMC6581568
OpenAlexW2749534302

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.